In Vivo Studies on the Inhibition of Coagulation by Fractionated Heparin and by a Heparin Analogue II. Effects of a Heparin Analogue

Summary

SSHA, a semi-synthetic heparin analogue, and sodium heparin from porcine intestinal mucosa were injected subcutaneously into six healthy volunteers over a period of three days in a cross-over trial. Before injection and 2, 4, 6, 8 hrs afterwards, the heparin like activity was measured with the APTT, the anti-Xa clotting test and two chromogenic substrate assays. The results show that SSHA mediates both anti-Xa and antithrombin activities in vivo. A comparison between the effects of SSHA and heparin is problematical due to the heterogeneity of different heparin preparations. Low doses of the analogue (45 mg s. c.) induced proportionally higher and longer lasting anti-Xa activities than higher doses (90 mg s. c.). Repeated injections of SSHA twice daily led to increasing effects on two tests for heparin-like activity, whereas two other tests remained unchanged. Both drugs were tolerated equally well, side effects were not detected. Clinical studies are required to demonstrate whether SSHA is similar or superior to low-dose heparin for use in thrombosis prophylaxis.

Keywords

Heparin analogue - Heparin - Thrombosis prophylaxis

• References

• 1 Lane DA, Michalski R, Van RossM E, Kakkar VV. Comparison of heparin and a semi-synthetic heparin-analogue, A 73025.I Kinetics of clearance from the circulation of man following intravenous injection. Br J Haematol 1977; 37: 239-245
• 2 Michalski R, Lane DA, Kakkar VV. Comparison of Heparin and a semi-synthetic heparin analogue, A 73025. II Some effects on platelet function. Br J Haematol 1977; 37: 247-256
• 3 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J DawesJ, Pepper DS. In-vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
• 4 Kakkar VV, Lawrence D, Bentley PG, de Haas HA, Ward VP, Scully MF. A comparative study of low doses of heparin and a heparin analogue in the prevention of postoperative deep vein thrombosis. Thromb Res 1978; 13: 111-122
• 5 Thomas DP, Michalski R, Lane DA, Johnson EA, Kakkar VV. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-122
• 6 Yin ET, Wessler S, Butler J. Plasma heparin: A unique, practical, submicrogram sensitive assay. J Lab Clin Med 1973; 81: 298-310
• 7 Larsen ML, Abildgaard U, Teien AN, Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res 1978; 13: 285-288
• 8 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using chromogenic substrate. Thromb Res 1976; 8: 413-416
• 9 Schmitz-Huebner U, Balleisen L, Asbeck F, van de Loo J. In-vivo studies on the inhibition of coagulation induced by a fractionated heparin and by a heparin analogue. I. Effects of heparin fractions Thromb Haemostas 1981; 46: 612-616
• 10 Ødegard OR. Evaluation of an amidolytic heparin cofactor assay method. Thromb Res 1975; 7: 351-360
• 11 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung von Fibrinogen. Acta Haematol 1957; 17: 237-246
• 12 Sachs L. (ed.) Angewandte Statistik. Springer; Berlin, Heidelberg, New York: 1978
• 13 Barrowcliffe TW, Johnson EA, Eggleton CA, Thomas DP. Anticoagulant activities of lung and mucous heparins. Thromb Res 1977; 12: 27-36
• 14 Lane DA, Macgregor IR, Michalski R, Kakkar VV. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res 1978; 12: 257-271
• 15 Chan V, Chan TK. Heparin-Antithrombin III binding. Haemostasis 1979; 8: 373-389
• 16 Wessler S. Mini-dose heparin. Thrombos Diathes Haemorrh 1975; 34: 718-726